These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31705486)

  • 41. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW; Craig WA; Andes D
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.
    Waites KB; Crabb DM; Duffy LB; Jensen JS; Liu Y; Paukner S
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
    Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
    Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tissue Distribution of [
    Wicha WW; Henson C; Webbley K; Gelone SP
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0035522. PubMed ID: 35862748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia.
    Leesik H; Ani U; Juhani A; Altraja A
    Medicina (Kaunas); 2006; 42(5):384-94. PubMed ID: 16778466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.
    Paukner S; Riedl R
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development, validation, and application of an LC-MS/MS method for the quantification of the novel antibiotic drug lefamulin (Xenleta®) and its main metabolite 2R-hydroxy lefamulin in human plasma.
    Strickmann DB; Faber J; Klaassen T
    J Pharm Biomed Anal; 2021 Oct; 205():114293. PubMed ID: 34464869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Wu S; Zheng Y; Guo Y; Yin D; Zhu D; Hu F
    Front Microbiol; 2020; 11():578824. PubMed ID: 33042095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Alexander Project--5 years in Poland].
    Hryniewicz W
    Pol Merkur Lekarski; 2003 Jan; 14(79):5-8. PubMed ID: 12712818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lefamulin for Treating Community-acquired Bacterial Pneumonia in Adult Patients Aged <65 Years.
    Tang HJ; Lai CC
    Clin Infect Dis; 2020 Sep; 71(6):1582. PubMed ID: 31822903
    [No Abstract]   [Full Text] [Related]  

  • 55. Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods.
    Zhang L; Wicha WW; Bhavnani SM; Rubino CM
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii27-iii34. PubMed ID: 30949708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.
    Sader HS; Flamm RK; Streit JM; Carvalhaes CG; Mendes RE
    Int J Infect Dis; 2018 Dec; 77():82-86. PubMed ID: 30315990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of a novel series of acylides active against community-acquired respiratory pathogens.
    Pandya M; Chakrabarti A; Rathy S; Katoch R; Venkataraman R; Bhateja P; Mathur T; Kumar GR; Malhotra S; Rao M; Bhadauria T; Barman TK; Das B; Upadhyay D; Bhatnagar PK
    Int J Antimicrob Agents; 2010 Aug; 36(2):169-74. PubMed ID: 20493666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
    Bartlett JG
    Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.